# Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

> **NCT00279825** · PHASE2 · COMPLETED · sponsor: **Impax Laboratories, LLC** · enrollment: 16 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** IPX054 200 mg
- **DRUG:** IPX054 250 mg
- **DRUG:** CD-LD IR
- **DRUG:** CD-LD CR
- **DRUG:** IPX054 200 mg Placebo
- **DRUG:** IPX054 250 mg Placebo
- **DRUG:** CD-LD IR Placebo
- **DRUG:** CD-LD CR Placebo

## Key facts

- **NCT ID:** NCT00279825
- **Lead sponsor:** Impax Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00279825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00279825, "Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00279825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*